Shoreline's proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cells to improve anti-cancer activity.
| Website | https://www.shorelinebio.com/ |
| Employees | 36 (36 on RocketReach) |
| Founded | 2020 |
| Industry | Biotechnology Research, Biotechnology, Drug Discovery |
| Keywords | Nk Cell Therapy, Cell Therapy, Cellular Therapy, Immunotherapy, Cell Engineering, Immuno-Oncology, Cancer Treatment, Regenerative Medicine, Oncology, Stem Cell Therapy, Clinical Trials, Biotechnology, Drug Development, Therapeutics, Precision Medicine, Biopharma, Pharmaceutical |
| Competitors | Bristol Myers Squibb, Novartis, Gilead Sciences, Adaptimmune, Kite Pharma, Allogene Therapeutics, Sorrento Therapeutics, Inc., Cellectis, bluebird bio, OncoQuest Inc +44 more (view full list) |
Looking for a particular Shoreline Biosciences, Inc. employee's phone or email?
Scott Forrest is the Chief Business Officer of Shoreline Biosciences, Inc..
36 people are employed at Shoreline Biosciences, Inc..
Shoreline Biosciences, Inc. is based in La Jolla, California.